Liu Jingping, Party Secretary and Chairperson of Huluwa Pharmaceutical Group, Successfully Elected Vice President of the China Association of Pharmaceutical Commerce

On November 17, the 9th General Assembly and the 1st Council Meeting of the 9th Council of the China Association of Pharmaceutical Commerce were held in Nanjing. Ms. Liu Jingping, Party Secretary and Chairperson of Huluwa Pharmaceutical Group, was elected Vice President of the China Association of Pharmaceutical Commerce. This honor fully reflects the Group's prominent position in the pharmaceutical commerce sector. 

As a member of the Association's leadership, Chairperson Liu Jingping will participate in formulating development strategies for the pharmaceutical commerce sector and promote key initiatives such as industry standardization. Moving forward, Huluwa Pharmaceutical Group will leverage its professional expertise in pediatric medicines to help build a more efficient pharmaceutical commerce ecosystem and contribute its wisdom and strength to the implementation of the Healthy China strategy.

The China Association of Pharmaceutical Commerce is a national first-class industry association, with its membership comprising leading enterprises in both the pharmaceutical commerce and manufacturing sectors across China. The election of Chairperson Liu Jingping not only recognizes her more than three decades of management experience and expertise in the pharmaceutical industry, but also reflects the industry standing of Huluwa Pharmaceutical Group. It further highlights the close alignment between the company’s corporate philosophy of "Professional Excellence and Innovation, Safeguarding Health" and the development direction of the pharmaceutical industry.

Looking ahead, Huluwa Pharmaceutical Group is set to launch the "Golden Escort" initiative, deepening its focus on pediatric pharmaceuticals while expanding into the adult medication market. While steadily advancing the development of its offline presence across three major end-point channels and six key markets, the Group will accelerate the construction of its online new retail platform. It will establish a closed-loop service integrating online consultations and home delivery of medications, leveraging technological innovation and convenient services to benefit public health and contribute to the Healthy China initiative.